<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2020.93025</article-id><article-id pub-id-type="publisher-id">HJO-37471</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20200300000_82306401.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  多波长激光联合曲安奈德球后注射治疗非增殖性糖尿病性视网膜病变黄斑水肿的临床观察
  The Observation of Clinical Results for Macular Edema of Nonproliferative Diabetic Retinopathy by Multiwavelength Laser Combined with Retrobulbar Injection of Triamcinolone Acetonide
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>学英</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>齐</surname><given-names>绍文</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>长娥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>惠春</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>解放军989医院平顶山医疗区眼科，河南 平顶山</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>09</month><year>2020</year></pub-date><volume>09</volume><issue>03</issue><fpage>191</fpage><lpage>196</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：评价多波长氪黄激光联合曲安奈德球后注射治疗非增殖性糖尿病性视网膜病变黄斑水肿的临床效果。方法：收集确诊为非增殖性糖尿病性视网膜病变黄斑水肿的患者，经同质化筛选后，确定共93例(136眼)有效病例，进行随机分组：治疗组47例(72眼)使用多波长氪黄激光黄斑光凝联合曲安奈德球后注射治疗；对照组39例(64眼)仅多波长氪黄激光黄斑光凝。治疗后进行随访，观察比较患者最佳矫正视力(Best corrected visual acuity, BCVA)和黄斑中心凹厚度(Determination of macular retinal thickness, DMT)。结果：两组组内比较，治疗3个月后，两组的最佳矫正视力(BCVA)均比治疗前提高明显(P &lt; 0.05)，差异具有统计学意义，黄斑中心凹厚度(DMT)明显小于治疗前(P &lt; 0.05)，差异具有统计学意义；两组组间比较，最佳矫正视力差异有显著性(P &lt; 0.05)，黄斑中心凹厚度在治疗6个月，无明显差异(P &gt; 0.05)。结论：多波长氪黄激光联合曲安奈德球后注射治疗非增殖性糖尿病性视网膜病变黄斑水肿的临床效果显著。
    Objective: To evaluate the clinical effect of multi wavelength krypton yellow laser combined with retrobulbar injection of triamcinolone acetonide in the treatment of macular edema in non-prolife- rative diabetic retinopathy. Methods: 93 cases of 136 eyes macular edema in patients with non-pro- liferative diabetic retinopathy, 72 eyes of which treated by multiwavelength laser combined with retrobulbar injection of triamcinolone acetonide, another 64 eyes treated by multi-wavelength laser, detectting and comparing the two groups of patients before and after treat, include best corrected visual acuity and determination of macular retinal thickness. Results: The best corrected visual acuity increased more significantly compared with preoperative (P &lt; 0.05) in both group after treat. The determination of macular retinal thickness decreased more significantly compared with preoperative (P &lt; 0.05). in both group after treated. The best corrected visual acuity had significient difference compared with two group after treat (P &lt; 0.05). The determination of macular retinal thickness had no significient difference compared with two group six months after treat (P &gt; 0.05). Conclusion: The clinical effect of multi wavelength krypton yellow laser combined with retrobulbar injection of triamcinolone acetonide in the treatment of macular edema by nonproliferative diabetic retinopathy is significant. 
  
 
</p></abstract><kwd-group><kwd>多波长氪黄激光，曲安奈德，糖尿病性视网膜病变，黄斑水肿, Multi-Wavelength Laser</kwd><kwd> Triamcinolone Acetonide</kwd><kwd> Nonproliferative Diabetic Retinopathy</kwd><kwd> 
Macular Edema</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：评价多波长氪黄激光联合曲安奈德球后注射治疗非增殖性糖尿病性视网膜病变黄斑水肿的临床效果。方法：收集确诊为非增殖性糖尿病性视网膜病变黄斑水肿的患者，经同质化筛选后，确定共93例(136眼)有效病例，进行随机分组：治疗组47例(72眼)使用多波长氪黄激光黄斑光凝联合曲安奈德球后注射治疗；对照组39例(64眼)仅多波长氪黄激光黄斑光凝。治疗后进行随访，观察比较患者最佳矫正视力(Best corrected visual acuity, BCVA)和黄斑中心凹厚度(Determination of macular retinal thickness, DMT)。结果：两组组内比较，治疗3个月后，两组的最佳矫正视力(BCVA)均比治疗前提高明显(P &lt; 0.05)，差异具有统计学意义，黄斑中心凹厚度(DMT)明显小于治疗前(P &lt; 0.05)，差异具有统计学意义；两组组间比较，最佳矫正视力差异有显著性(P &lt; 0.05)，黄斑中心凹厚度在治疗6个月，无明显差异(P &gt; 0.05)。结论：多波长氪黄激光联合曲安奈德球后注射治疗非增殖性糖尿病性视网膜病变黄斑水肿的临床效果显著。</p></sec><sec id="s2"><title>关键词</title><p>多波长氪黄激光，曲安奈德，糖尿病性视网膜病变，黄斑水肿</p></sec><sec id="s3"><title>The Observation of Clinical Results for Macular Edema of Nonproliferative Diabetic Retinopathy by Multiwavelength Laser Combined with Retrobulbar Injection of Triamcinolone Acetonide</title><p>Xueying Song, Shaowen Qi, Chang’e Hu, Huichun Yang<sup>*</sup></p><p>Department of Ophthalmology, No. 989 Hospital of PLA, Pingdingshan Henan</p><p><img src="//html.hanspub.org/file/5-2230294x5_hanspub.png" /></p><p>Received: Aug. 14<sup>th</sup>, 2020; accepted: Aug. 28<sup>th</sup>, 2020; published: Sep. 4<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/5-2230294x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluate the clinical effect of multi wavelength krypton yellow laser combined with retrobulbar injection of triamcinolone acetonide in the treatment of macular edema in non-prolife- rative diabetic retinopathy. Methods: 93 cases of 136 eyes macular edema in patients with non-pro- liferative diabetic retinopathy, 72 eyes of which treated by multiwavelength laser combined with retrobulbar injection of triamcinolone acetonide, another 64 eyes treated by multi-wavelength laser, detectting and comparing the two groups of patients before and after treat, include best corrected visual acuity and determination of macular retinal thickness. Results: The best corrected visual acuity increased more significantly compared with preoperative (P &lt; 0.05) in both group after treat. The determination of macular retinal thickness decreased more significantly compared with preoperative (P &lt; 0.05). in both group after treated. The best corrected visual acuity had significient difference compared with two group after treat (P &lt; 0.05). The determination of macular retinal thickness had no significient difference compared with two group six months after treat (P &gt; 0.05). Conclusion: The clinical effect of multi wavelength krypton yellow laser combined with retrobulbar injection of triamcinolone acetonide in the treatment of macular edema by nonproliferative diabetic retinopathy is significant.</p><p>Keywords:Multi-Wavelength Laser, Triamcinolone Acetonide, Nonproliferative Diabetic Retinopathy, Macular Edema</p><disp-formula id="hanspub.37471-formula20"><graphic xlink:href="//html.hanspub.org/file/5-2230294x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-2230294x8_hanspub.png" /> <img src="//html.hanspub.org/file/5-2230294x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>随着糖尿病(DM)患病率的逐年上升 [<xref ref-type="bibr" rid="hanspub.37471-ref1">1</xref>]，糖尿病视网膜病变(Diabetes retinopathy, DR)作为DM最为常见和严重的微血管并发症之一也呈增长趋势，已成为中老年人视力丧失的主要原因 [<xref ref-type="bibr" rid="hanspub.37471-ref2">2</xref>]。糖尿病性黄斑水肿(DME)是糖尿病性视网膜病变(DR)最常见的并发症，也是造成糖尿病患者视力下降的主要因素之一 [<xref ref-type="bibr" rid="hanspub.37471-ref3">3</xref>]。DME会引起中心视力的急剧下降。1990年激光光凝成为DME的标准治疗方案 [<xref ref-type="bibr" rid="hanspub.37471-ref4">4</xref>]。目前临床常用的治疗方法主要有药物治疗联合激光光凝，药物主要有糖皮质激素曲安奈德与抗VEGF，而抗VEGF较为昂贵，不易推广。本文主要研究多波长氪黄激光联合曲安奈德球后注射治疗非增殖性糖尿病性视网膜病变黄斑水肿的临床效果。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>病例来源于我院眼科2015年1月~2018年1月期间确诊的非增殖性糖尿病性视网膜病变患者，共93例(136眼)有效病例，纳入标准：1) 2型糖尿病患者，血糖控制好，糖化血红蛋白 ≤ 10%；2) 累及中心凹的DME；3) 黄斑中心凹视网膜厚度(Central macular thickness, CMT) &gt; 250 μm；4) 无影响检查眼底 的屈光间质混浊或瞳孔缩小；5) 无其他原因引起的黄斑水肿；6) 随访期间未行全视网膜激光光凝治疗。治疗组47例(72眼)其中男性29人，女性18人，平均年龄56 &#177; 7.4岁。同时选择同期内未联合曲安奈德注射治疗的糖尿病黄斑水肿患者39例(64眼)作为对照组，其中男性26人，女性13人，平均年龄55 &#177; 4.3岁。所有治疗及操作均经医院伦理委员会批准同意。</p></sec><sec id="s6_2"><title>2.2. 方法</title><sec id="s6_2_1"><title>2.2.1. 激光方法</title><p>首先使用美多丽(0.5%复方托吡卡胺滴眼液)散瞳，经充分散瞳后1%奥布卡因表面麻醉 [<xref ref-type="bibr" rid="hanspub.37471-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.37471-ref6">6</xref>]，共计2次，使用全视网膜镜观测眼底，采用多波长氪激光光凝治疗，其中氪黄激光治疗波长568 nm；光凝部位根据眼底荧光造影显示结果确定光凝区域，主要光凝区域为视网膜微动脉瘤所在区域，还包括毛细血管渗漏区 [<xref ref-type="bibr" rid="hanspub.37471-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.37471-ref8">8</xref>]。激光功率范围75~200 mw。在黄斑区内采用50~l00 mw，120 μm光斑直径，间距l00~200 pm，曝光时间0．10~0.15 s [<xref ref-type="bibr" rid="hanspub.37471-ref9">9</xref>]。对弥漫性黄斑水肿，在黄斑无血管区内的边缘至血管弓以内避开视乳头黄斑束，用2~3排75~100 μm的光斑做C型格栅状光凝。每眼光凝点数约为1500~2300点，光斑反应I~II级。</p></sec><sec id="s6_2_2"><title>2.2.2. 曲安奈德注射</title><p>激光治疗后给予患者每眼球后注射曲安奈德(RBTA)，摇匀0.5 mL/20 mg曲安奈德，在眼眶下缘处中外1/3交界线处偏上2 mm处进针，首先针头与皮肤保持垂直缓慢进针约1 cm，后将针头向内上方缓慢插入，直至眼眶内部，到达球后，先向注射器内回抽，如未发现回血现象则向球后注入曲安奈德0.5 mL/20 mg，常规按压。</p></sec></sec><sec id="s6_3"><title>2.3. 观察项目</title><p>通过电脑验光使用国际标准视力表检查最佳矫正视力(BCVA)，再转换为最小分辨角的对数视力(LogMAR)，记录治疗后第1月、3月及6月的值和黄斑中心凹厚度(DMT)的变化。并密切监测双眼眼压、眼部感染情况及有无治疗后并发症的发生。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS统计软件，数据用平均值 &#177; 标准差(&#177;S)表示。组内均值比较采用t的检验，多组间比较采用Kruskal-wallis检验。P &lt; 0.05认为具有显著统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 最佳矫正视力</title><p>治疗前后最佳矫正视力(BCVA)比较，治疗6个月后比治疗前提高明显(P &lt; 0.05)，差异具有统计学意义(见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of the best corrected visual acuity (LogMAR, χ&#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后1月</th><th align="center" valign="middle" >治疗后3月</th><th align="center" valign="middle" >治疗后6月</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >0.33 &#177; 0.07</td><td align="center" valign="middle" >0.38 &#177; 0.16</td><td align="center" valign="middle" >0.63 &#177; 0.27</td><td align="center" valign="middle" >0.67 &#177; 0.22</td><td align="center" valign="middle" >P &lt; 0.05</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >0.35 &#177; 0.11</td><td align="center" valign="middle" >0.36 &#177; 0.03</td><td align="center" valign="middle" >0.60 &#177; 0.13</td><td align="center" valign="middle" >0.62 &#177; 0.14</td><td align="center" valign="middle" >P &lt; 0.05</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >P &gt; 0.05</td><td align="center" valign="middle" >P &lt; 0.05</td><td align="center" valign="middle" >P &lt; 0.05</td><td align="center" valign="middle" >P &lt; 0.05</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 最佳矫正视力(BCVA)比较(LogMAR, χ&#177; s)</p></sec><sec id="s7_2"><title>3.2. 黄斑区视网膜厚度</title><p>采用OCT检查黄斑区视网膜厚度(Macular retinal thickness, MRT)，检测黄斑中央区1 mm范围内平均视网膜厚度，MRT ≤ 250 μm 为正常，250 μm &lt; MRT &lt; 500 μm为中度水肿，MRT ≥ 500 μm者为重度水肿。黄斑中心凹厚度(DMT)明显小于治疗前(P &lt; 0.05)，差异具有统计学意义(见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of determination of macular retinal thickness (χ &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后1月</th><th align="center" valign="middle" >治疗后3月</th><th align="center" valign="middle" >治疗后6月</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >380.17 &#177; 45.07</td><td align="center" valign="middle" >294.11 &#177; 57.26</td><td align="center" valign="middle" >221.77 &#177; 45.78</td><td align="center" valign="middle" >196.32 &#177; 24.36</td><td align="center" valign="middle" >P &lt; 0.05</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >374.21 &#177; 51.75</td><td align="center" valign="middle" >321.21 &#177; 40.12</td><td align="center" valign="middle" >253.64 &#177; 51.88</td><td align="center" valign="middle" >199.02 &#177; 20.13</td><td align="center" valign="middle" >P &lt; 0.05</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >P &gt; 0.05</td><td align="center" valign="middle" >P &lt; 0.05</td><td align="center" valign="middle" >P &lt; 0.05</td><td align="center" valign="middle" >P &gt; 0.05</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 黄斑中心凹厚度(DMT)比较(χ &#177; s)</p></sec><sec id="s7_3"><title>3.3. 患者治疗前后眼压</title><p>治疗组眼压治疗前平均眼压14.22 &#177; 3.47 mmHg，随访1月时平均眼压16.69 &#177; 3.52 mmHg。对照组眼压治疗前平均眼压15.46 &#177; 4.23 mmHg，随访1月时平均眼压15.59 &#177; 3.43 mmHg。</p></sec><sec id="s7_4"><title>3.4. 并发症</title><p>治疗组1眼球后注射后眼外出血，给予药物治疗后吸收。术后一过性高眼压7眼，均出现在术后12~14 d，减少局部激素滴眼液使用和点用降眼压滴眼液后，眼压控制在正常范围。两组治疗后均无眼内出血、医源性视网膜裂孔、眼内感染、晶状体损伤并发症。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>糖尿病黄斑水肿(DME)是糖尿病视网膜病变患者视力减退的主要原因 [<xref ref-type="bibr" rid="hanspub.37471-ref10">10</xref>]。按照DR的发展阶段和严重程度，临床上又分为非增殖性(Nonproliferative diabetic retinopathy, NPDR)和增殖性(Proliferative diabetic retinopathy, PDR)。根据NPDR病情的发展程度，分为I~III期，其中最早期的表现是微血管瘤，该病变常首先出现在眼底的后极部和黄斑区 [<xref ref-type="bibr" rid="hanspub.37471-ref11">11</xref>]。微血管瘤造成的渗漏是黄斑水肿的重要原因。DME的治疗目的在于减轻水肿、改善视力，首选激光光凝治疗 [<xref ref-type="bibr" rid="hanspub.37471-ref12">12</xref>]。研究显示，局灶光凝、格栅激光或两者均可有效降低DME引起的中度视力丧失的风险，早期激光光凝可降低DME患者视力丧失的风险，少数患者视力可得到改善 [<xref ref-type="bibr" rid="hanspub.37471-ref4">4</xref>]。一项回顾性研究发现：眼底激光光凝术后16.5%的患者视力提高2行以上，视力不变者占67.7%，同时该研究显示激光术后黄斑水肿消退和减轻占84.1% [<xref ref-type="bibr" rid="hanspub.37471-ref13">13</xref>]。</p><p>通过激光光凝黄斑区微动脉瘤及毛细血管可以封闭异常渗漏，消除黄斑区水肿，而对黄斑区C形格栅样光凝，可清除异常的视网膜色素上皮细胞，促进新生细胞生长，重建视网膜外屏障 [<xref ref-type="bibr" rid="hanspub.37471-ref14">14</xref>]。但由于激光本身的特性，导致单一波长的激光在治疗糖尿病性视网膜病变这种复杂的眼底病时受限明显，这就需要根据病变的不同使用不同波长的激光进行治疗，而多波长激光就显示出其优越性了 [<xref ref-type="bibr" rid="hanspub.37471-ref15">15</xref>]。</p><p>近几年来，玻璃体腔注射雷珠单抗等抗VEGF药物显示其提高视力明显、副作用小，成为目前DME的一线治疗方法，但易复发需多次重复注射，造成巨大的经济负担，并增加出血、感染、脑血管意外等相关的并发症 [<xref ref-type="bibr" rid="hanspub.37471-ref16">16</xref>]。曲安奈德是一种非水溶性人工合成的长效糖皮质激素，具有抗新生血管生成、消炎、抑制细胞增生等作用，最早开始应用于治疗葡萄膜炎并发或内眼手术引起的黄斑水肿 [<xref ref-type="bibr" rid="hanspub.37471-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.37471-ref18">18</xref>]。曲安奈德治疗黄斑水肿的疗效已得到有力证实 [<xref ref-type="bibr" rid="hanspub.37471-ref19">19</xref>]，曲安奈德广泛应用于DME的治疗，具有较强抗炎、抗新生血管生成、抑制细胞增殖的作用，可明显减轻黄斑水肿，提高视力，尤其对激光光凝治疗无效的患者疗效尤佳 [<xref ref-type="bibr" rid="hanspub.37471-ref20">20</xref>]。其抗炎作用能阻滞巨噬细胞、淋巴细胞及补体参与水肿炎性反应，稳定溶酶体酶，稳定血–视网膜屏障 [<xref ref-type="bibr" rid="hanspub.37471-ref21">21</xref>]。通过给药方式研究证实黄斑水肿治疗中药物后Tenon囊下注射疗效较玻璃体内注射高 [<xref ref-type="bibr" rid="hanspub.37471-ref22">22</xref>]。资料显示 [<xref ref-type="bibr" rid="hanspub.37471-ref23">23</xref>] 玻璃体内注射给药4 mg，药物直接从玻璃体腔及前房部消失需要3个月左右，而球后注射给药20 mg，在3个月后仍可从房水中检测到药物的存在，充分说明两种给药方式所维持的效果不相上下。但球后注射组的并发症发生率低于玻璃体内注射组，通过分析主要原因是球后注射，可以避免在眼内操作的危险性，且球后注射可以使药效间接作用于球部，因此可以减少并发症的发生。国外也有研究发现，曲安奈德后Tenon囊下注射，可促使药物在球内长时间维持稳定的有效治疗量，以更好发挥作用 [<xref ref-type="bibr" rid="hanspub.37471-ref24">24</xref>]。因此球后注射TA风险较小，且能反复进行，在临床上有较大的应用价值。</p><p>激光治疗后球后注射TA，能更有效消除黄斑水肿，保护视功能，提高视力，联合治疗方案治疗DME可以减少单药剂量及重复治疗次数、或降低激光光凝能量，减轻对视网膜的损伤，从而减少并发症，有效保存视网膜功能，且联合治疗能更大程度的降低VEGF的含量，且光凝刺激色素上皮生长因子(Pigment epithelium growth factor, PEGF)的产生增加，二者协同发挥促新生血管的消退，且通过减少激光的能量和TA的用量减轻并发症的发生。本研究中，治疗组患者的视力、黄斑水肿情况得到明显缓解，而无明显并发症发生。多波长氪黄激光光凝联合球后注射TA极大提高了糖尿病性视网膜病变黄斑水肿的疗效和安全性，适宜在基层医院推广。</p></sec><sec id="s9"><title>文章引用</title><p>宋学英,齐绍文,胡长娥,杨惠春. 多波长激光联合曲安奈德球后注射治疗非增殖性糖尿病性视网膜病变黄斑水肿的临床观察 The Observation of Clinical Results for Macular Edema of Nonproliferative Diabetic Retinopathy by Multiwavelength Laser Combined with Retrobulbar Injection of Triamcinolone Acetonide[J]. 眼科学, 2020, 09(03): 191-196. https://doi.org/10.12677/HJO.2020.93025</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37471-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Yang, W., Lu, J., Weng, J., et al. (2010) Prevalence of Diabetes among Men and Women in China. The New England Journal of Medicine, 362, 1090-1091. https://doi.org/10.1056/NEJMoa0908292</mixed-citation></ref><ref id="hanspub.37471-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Klein, B.E. (2007) Overview of Epidemiologic Studies of Diabetic Retinopathy. Ophthalmic Epidemiology, 14, 179-183.  
https://doi.org/10.1080/09286580701396720</mixed-citation></ref><ref id="hanspub.37471-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">张大卫, 张蕊, 杨敏, 等. 球周注射曲安奈德联合全视网膜光凝治疗糖尿病黄斑水肿疗效观察[J]. 疑难病杂志, 2016, 15(12): 1263-1267.</mixed-citation></ref><ref id="hanspub.37471-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Alvi, R., Memon, M.S., Shera, S., et al. (2016) Visual Outcome of Laser Treatment in Diabetic Macular Edema: Study from an Urban Diabetes Care Center. Pakistan Journal of Medical Sciences, 32, 1229-1233.  
https://doi.org/10.12669/pjms.325.10597</mixed-citation></ref><ref id="hanspub.37471-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">徐静娴, 张贤亮, 石壮, 等. 糖尿病视网膜病变激光光凝术后黄斑区脉络膜厚度变化的观察[J]. 中国实用眼科杂志, 2015, 33(6): 598-602.</mixed-citation></ref><ref id="hanspub.37471-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">梁丽, 单明华, 徐斌, 等. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗视网膜静脉阻塞并发黄斑水肿的疗效比[J]. 河北医科大学学报, 2015, 33(3): 356-358.</mixed-citation></ref><ref id="hanspub.37471-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Bressler, N.M., Beck, R.W., Ferris, F.L., et al. (2011) Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. The New England Journal of Medicine, 16, 2234-237. https://doi.org/10.1056/NEJMct0908432</mixed-citation></ref><ref id="hanspub.37471-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">张磊, 刘大川, 吴航. 糖尿病视网膜病变患眼激光光凝治疗前后黄斑区脉络膜厚度的增强深部成像技术测量[J]. 中华眼底病杂志, 2014, 30(6): 562-565.</mixed-citation></ref><ref id="hanspub.37471-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">卢百阳, 武志峰, 孙松, 等. 全视网膜光凝对糖尿病视网膜病变神经纤维层及黄斑厚度的影响[J]. 山东医药, 2010, 50(32): 12-15.</mixed-citation></ref><ref id="hanspub.37471-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">董秀清, 冯松福, 柯晓云. 应用光学相干断层扫描量化评估糖尿病黄斑水肿的临床研究[J]. 眼科新进展, 2017, 37(2): 133-136.</mixed-citation></ref><ref id="hanspub.37471-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">刘祥杰. 糖尿病性视网膜病变激光治疗时机[J]. 临床医学, 2015(3): 95-96.</mixed-citation></ref><ref id="hanspub.37471-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Avery, R.L. and Gordon, G.M. (2016) Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-Analysis. JAMA Ophthalmology, 134, 21-29.  
https://doi.org/10.1001/jamaophthalmol.2015.4070</mixed-citation></ref><ref id="hanspub.37471-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">齐慧君, 黎晓新. 糖尿病性黄斑水肿的激光治疗[J]. 眼科, 2005, 14(4): 234-236.</mixed-citation></ref><ref id="hanspub.37471-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">刘新, 邹吉新, 张立军, 等. PASCAL激光一次性全视网膜光凝治疗增殖性糖尿病视网膜病变[J]. 国际眼科杂志, 2016, 16(4): 712-715.</mixed-citation></ref><ref id="hanspub.37471-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Hu, Y., Zhang, T., Wang, K., et al. (2015) Changes in Choroidal Thickness after Panretinal Photocoagulation in Patients with Type 2 Diabetes. Retina, 35, 695-703. https://doi.org/10.1097/IAE.0000000000000381</mixed-citation></ref><ref id="hanspub.37471-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. (2012) Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology, 119, 789-801.  
https://doi.org/10.1016/j.ophtha.2011.12.039</mixed-citation></ref><ref id="hanspub.37471-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Massin, P., Audren, F., Haouchine, B., Erginay, A., Bergmann, J.F., Benosman, R., et al. (2004) Intravitreal Triamcinolone Acetonide for Diabetic Diffuse Macular Edema Preliminary Results of a Prospective Controlled Trial. Ophthalmology, 111, 218-224. https://doi.org/10.1016/j.ophtha.2003.05.037</mixed-citation></ref><ref id="hanspub.37471-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Jonas, J.B., Kreisig, I. and Sotker, A. (2003) Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema. Archives of Ophthalmology, 121, 57-61. https://doi.org/10.1001/archopht.121.1.57</mixed-citation></ref><ref id="hanspub.37471-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Bonini-Filho, M.A., Jorge, R., Barbosa, J.C., et al. (2005) Intravitreal Injection versus Sub-Tenon’s Infusion of Triamcinolone Ace-Tonide for Refractory Diabetic Macular Edema: A Randomized Clinical Trial. Investigative Ophthalmology &amp; Visual Science, 46, 3845-38499. https://doi.org/10.1167/iovs.05-0297</mixed-citation></ref><ref id="hanspub.37471-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">潘竹娟, 张志辉, 樊飞红, 等. 全视网膜光凝联合雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效及费用比较[J]. 国际眼科杂志, 2018, 18(4): 682-685.</mixed-citation></ref><ref id="hanspub.37471-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">翁宏武, 王柯鳗, 马海智, 等. 玻璃体内注射曲安奈德联合黄斑部格栅样光凝治疗弥漫性糖尿病性黄斑水肿[J]. 眼科新进展, 2016, 36(11): 1050-1053.</mixed-citation></ref><ref id="hanspub.37471-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">褚梦琪. 视网膜静脉阻塞继发黄斑水肿的最新治疗进展[J]. 中华实验眼科杂志, 2018, 36(1): 65.</mixed-citation></ref><ref id="hanspub.37471-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">谢碧华, 何宇, 辛梅, 等. 曲安奈德与雷珠单抗辅助治疗弥漫性糖尿病性黄斑水肿的疗效比较[J]. 国际眼科杂志, 2018, 18(6): 1089-1092.</mixed-citation></ref><ref id="hanspub.37471-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Pak, K.Y., Choi, B.S., Park, S.W., et al. (2017) Comparison of Vitrectomized with Nonvitrectomized Eyes after Subtenon Injection of Triamcinolone Acetonide to Treat Diabetic Macular Edema: Retrospective Comparative Analysis of an Interventional Case Series. Indian Journal of Ophthalmology, 65, 488-492. https://doi.org/10.4103/ijo.IJO_627_16</mixed-citation></ref></ref-list></back></article>